Here are the hepatitis treatment news stories with the most views this year:
1. Harvoni Is Mostly Cost Effective, But Budget Impact Will Be Huge
Posted: March 25
2. BMS Resubmits FDA Application for Hepatitis C Drug Daclatasvir
Posted: March 12
3. Gilead’s All-Genotype Hep C Drug Boasts Excellent Cure Rates
Posted: September 23
4. FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3
Posted: July 24
5. Retreatment With 24 Weeks of Harvoni Often Cures Hepatitis C
Posted: May 4
6. Liver Association Updates Hepatitis C Treatment Guidelines
Posted: July 21
7. ACH-3102 and Sovaldi Have 100% Hepatitis C Cure Rate in 6 Weeks
Posted: February 11
8. Could a Cancer Drug Cure Hepatitis B?
Posted: May 6
9. Daklinza/Sovaldi Success for Those With HIV/HCV
Posted: August 5
10. Harvoni Boasts Near-Perfect Hep C Cure Rates in Cirrhotics
Posted: May 20
11. More Perfect Cure Rates for Achillion’s Six-Week Hep C Treatment
Posted: September 28
12. High Rates of Advanced Liver Damage in Hep C-Diagnosed Boomers
Posted: March 11
13. Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes
Posted: October 30
14. One Million Americans With Hep C Have High-Priority Treatment Status
Posted: January 14
15. 96% Hep C Cure Rate for Harvoni in Those Coinfected With HIV
Posted: March 3
16. Sovaldi or Harvoni and Heart Med Cordarone Can Be a Fatal Mix
Posted: March 23
17. FDA Green Lights AbbVie’s Technivie for Genotype 4 of Hepatitis C
Posted: July 24
18. Merck Seeks FDA Approval of Hep C Tablet Grazoprevir/Elbasvir
Posted: June 1
19. Urgency of Hep C Treatment Rises as Fibrosis Advances
Posted: November 25
20. High Rates of Liver Disease in People With Long-Term Hep C
Posted: August 12

Istock (Model(s) used for illustrative purposes only)
Comments
Comments